A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Sep 24, 2026 - P1 | N=10 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | Trial completion date: May 2027 ➔ Sep 2026 | Trial primary completion date: May 2027 ➔ Sep 2026
Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|